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Abstract 
Context: High serum levels of thyroid stimulating hormone (TSH) have been associated with adverse 
pregnancy outcomes by some studies; and not by others.  
Objective: To assess the association between high levels of TSH in first trimester of pregnancy and 
adverse pregnancy outcomes; and examine the predictive accuracy as a screening test. 
Setting and Participants:  Serum levels of TSH were measured in a cohort of 2,801 women with a 
singleton pregnancy attending first trimester Down syndrome screening. Information on maternal and 
infant outcomes was obtained through record linkage to population-based birth and hospital data. 
Association between high TSH (>95th and >97.5th centile) multiple of the median (MoM) levels and 
risk of adverse pregnancy outcomes was evaluated using multivariable logistic regression and the 
predictive accuracy of models was assessed.  
Main Outcomes:  Small for gestational age (SGA), preterm birth, preeclampsia, miscarriage and 
stillbirth. 
Results: High TSH MoM levels were associated with SGA (<10th centile)  (adjusted odds ratio (aOR) 
1.71; 95%CI 0.99-2.94), preterm birth <37 weeks gestation (aOR 2.59; 95%CI 1.21-5.53), 
miscarriage (aOR 3.66; 95%CI 1.59-8.44) and a composite measure of any study outcome (aOR 2.10; 
95%CI 1.23–3.59). The area under the receiver operator characteristic curves were 0.69 (95% CI 
0.65-0.73) for SGA; 0.56 (95%CI 0.51-0.61) for preterm birth, 0.70 (95% CI 0.61-0.79) for 
miscarriage and 0.63 (95%CI 0.60–0.65) for any adverse pregnancy outcome. 
Conclusions: High TSH serum levels during first trimester of pregnancy were associated with 
adverse pregnancy outcomes; however the predictive accuracy was poor. Screening for high TSH 
levels in first trimester would be of no benefit to identify women at-risk. 
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Introduction 
 
The effect of thyroid malfunction in pregnancy and on subsequent pregnancies and infant outcomes is 
a subject of interest and controversy (1).  In vitro studies suggest that thyroid hormones contribute 
directly to early placental development stimulating angiogenesis, and promoting invasion and 
differentiation of embryonic cells (2, 3). Thyroid hormone (T3) receptors are present in the 
trophoblast and thyroid hormone transporters are significantly reduced in pregnancies with 
intrauterine growth restriction (4). These findings attest to  a possible effect of abnormal levels of 
thyroid hormones on the pathological pathways to adverse pregnancy outcomes.  
 
 Fetal thyroxine production does not occur until 8-10 weeks, therefore, the fetus depends upon 
maternal thyroid hormone transfer in early pregnancy for normal brain development (5, 6). 
Neurological impairment in children has been associated with maternal overt hypothyroidism (7) and 
hypothyroxinemia (8). Subclinical hypothyroidism is diagnosed in women with thyroid stimulating 
hormone (TSH) above a statistically defined upper limit of a reference range but normal levels of free 
thyroxine (fT4) (9). Although, some studies have reported increased rates of pregnancy loss (10, 11), 
placental abruption (12), preterm delivery (12) and preeclampsia (13) in woman with elevated TSH 
level, other studies have not identified a significant association with any adverse pregnancy outcome 
(14, 15).  
 
These inconsistent findings have led to conflicting support for screening asymptomatic women for 
high TSH levels in early pregnancy. Furthermore, studies suggests screening and treating women with 
subclinical hypothyroidism would be cost-effective if this resulted in improved child 
neurodevelopment (16, 17). First trimester screening would also provide an ideal opportunity to 
identify pregnancies at-risk and may be incorporated into existing routine antenatal testing when 
preventive interventions may be a realistic option. Despite these potential benefits and that a recent 
study found that screening and treating pregnant women with subclinical hypothyroidism was 
beneficial (18), current clinical guidelines by the American Thyroid Association highlight that there is 
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insufficient evidence to recommend it (19). There is also little information on the predictive accuracy 
of screening for TSH to identify pregnancies at risk.  
  
The aim of this study was to evaluate the association between high maternal TSH levels measured at 
10 to 14 weeks of pregnancy and the risk of adverse pregnancy outcomes; and to assess the predictive 
accuracy of TSH in predicting adverse outcomes in an unselected pregnant population.  
 
Methods 
 
Study Population and data sources 
The study population included pregnant women who had first trimester Down syndrome screening 
between July & October 2006 by The Pacific Laboratory Medicine Services (PaLMs), a pathology 
screening service in New South Wales (NSW), Australia. This was the state’s only public screening 
service and received samples from throughout NSW. A total of 3,103 serum samples were collected 
for women undergoing screening at 10-14 weeks gestation in pregnancy and all samples were 
archived at -80°C.  
 
Serum TSH levels were measured by automated immunoassay system (Siemens IMMULITE® 2000, 
Siemens Medical Solutions Diagnostics, Los Angeles, CA). The inter and intra assay coefficient of 
variation was <8% and the reported analytic sensitivity of the immunoassay was 0.004 IU/L. The 
samples were analysed blind to the clinical outcomes. 
 
Pregnancy and birth information for mothers and babies was ascertained from birth and hospital data 
and individual data were record-linked to each woman’s corresponding laboratory (Down syndrome 
and TSH) results. Birth information was obtained from the NSW Perinatal Data Collection (PDC), a 
statuary collection of all livebirths and stillbirths in NSW of at least 400 grams birth weight, or at least 
20 weeks gestation. It contains demographic, medical and obstetric information on the mother and 
information on the labor, delivery and condition of the infant. Hospital data were obtained from the 
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NSW Admitted Patient Data Collection (APDC), a census of hospital discharges from all NSW public 
and private hospitals and day procedure centres. It includes demographic, administrative and clinical 
information for each hospital admission. Information includes reason for admission, significant co-
morbidities and complications, and procedures performed during the admission. Up to 20 diagnosis 
and procedure fields were available for each admission and coded according to the 10th revision of the 
International Classification of Diseases – Australian Modification (ICD10-AM) and the 5th edition of 
the Australian Classification of Health Interventions (AHCI) respectively.   
 
In Australia unique identifiers are not available for record linkage of unit record data from multiple 
datasets (20).  Consequently probabilistic linkage methods were utilised. This involves a complex 
process of blocking and matching combinations of selected variables (such as name, date of birth, 
address and hospital) using record-linkage software (21). Probability weights are calculated, adjusted 
for incomplete and missing data, and used to determine correct matches. The validity of the 
probabilistic record linkage is extremely high with less than 1% of records having an incorrect match 
(20-23). The NSW Centre for Health Record Linkage conducted the record linkage and identifying 
information was removed prior to the release of data for analysis. The study was approved by the 
NSW Population and Health Services Research Ethics Committee.  
 
Linked health information relevant to the pregnancy was available for 2,907 (93.7%) samples. 
Importantly, there was no significant difference in TSH levels, maternal age and weight  for women 
whose health information was not available compared to those included in the study. We then 
excluded 106 women whose blood sample was taken before 10 or after 14 weeks gestation, had a 
medical abortion, had a twin pregnancy or had an infant with major congenital anomalies.  The study 
outcomes assessed included: small for gestational age (SGA), preterm birth, preeclampsia, 
miscarriage, stillbirth and a composite outcome of any adverse pregnancy outcome. SGA was defined 
as birthweight less than the 10th centile and less than the 3rd centile (severe SGA) of the distribution 
for gestational age and infant sex (24). Gestational age is reported in the birth data in completed 
weeks of gestation and determined by the best clinical estimate including early ultrasound (>97%) and 
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last menstrual period. Preterm birth was defined as delivery at less than 37 weeks and very preterm 
birth less than 34 weeks gestation. Information on preeclampsia was obtained from the hospital data, 
based on a diagnosis by the attending clinician that was coded according to ICD10-AM. During the 
study period, preeclampsia was defined as the onset of hypertension (systolic blood pressure ≥140 
mm Hg and/or diastolic blood pressure ≥90 mm Hg) from 20 weeks’ gestation onwards accompanied 
by proteinuria (25). Miscarriage was defined as a spontaneous pregnancy loss between 10-20 weeks 
gestation and were identified from hospital data. Stillbirth was defined as a pregnancy loss after 20 
weeks gestation and were identified from birth data. A composite ‘any adverse pregnancy outcome’ 
variable was also developed comprising the occurrence of any of the pregnancy outcomes from above. 
 
Explanatory variables applied in this study included; maternal age, parity (nulliparous/multiparous), 
smoking during pregnancy (yes/no), maternal weight (kilograms) and free β-hCG (corrected for 
gestational age at testing and maternal weight) collected at Down syndrome screening. Only factors 
that are well and accurately reported were included in the analyses (20, 26, 27). Maternal weight was 
missing in 550 (20%) of the records. We conducted a sensitivity analysis comparing model results 
when we included women with records missing weight assigning them with the mean weight of the 
total population, against excluding them from the analysis. As no significant difference was found, 
mean weight was applied to those missing values and included in the analyses. Other missing data 
were infrequent: there were no records with missing maternal age or parity. Smoking was missing in 
58 records (2.1%) and there were 4 missing records for free β-hCG (0.1%) which were excluded from 
the analysis. Only SGA analyses were affected by the missing data exclusions and importantly, there 
were no SGA cases with missing data. 
 
Statistical analysis 
We compared women with each study outcome to those without the adverse outcome. Descriptive 
statistics were calculated and differences between groups were tested using Chi-squared and Fisher’s 
exact test for categorical variables and student’s t-test for continuous variables. Given a non linear 
distribution of the serum levels of TSH, a non-parametric Kruskal-Wallis test was used to determine 
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differences among medians of gestational age at testing grouped in weeks, and the Wilcoxon rank-
sum test to determine differences in median TSH serum levels between mothers with and without 
each outcome of interest. 
 
As TSH differed by gestational week at testing, we standardized TSH levels using Multiple of the 
Medians (MoM) as described by Cuckle and Wald(28). A regression model was fitted to the medians 
for each week of gestation at testing for the unaffected group and each individual value was divided 
by its regressed value to calculate each MoM. Logistic regression was used to determine the 
association between maternal TSH (MoM) and adverse pregnancy outcomes. TSH (MoM) levels were 
dichotomized to identify mothers with high values of TSH using percentile cut-offs above the 95th 
(2.92, n=140) and 97.5th (3.74, n=70) percentiles. Backward elimination method was then used to fit 
models with only significant explanatory variables retained. Results are reported as adjusted odds 
ratios (aOR) with 95 percent confidence intervals (95% CI). 
 
The diagnostic performance of significant outcomes was assessed by examining the area under the 
Receiver Operating Characteristics (ROC) curves (AUC), derived from logistic regression analysis 
and using the TSH (MoM) 97.5th centile cut-off, as this was considered to be more clinically 
meaningful. AUC was calculated for both univariate and multivariable models and results examined 
whether the test performed better than chance (0.5).  A standardized scale was used to assess the AUC 
result (29) where an AUC of 1 represents a perfect test, 0.9 – <1 an excellent test, 0.8 – <0.9 a good 
test, 0.7 – <0.8 a fair test, 0.6 – <0.7 a poor test and 0.5 – <0.6 a worthless test. Finally, estimates of 
predictive accuracy were calculated including sensitivity, specificity, positive (PPV) and negative 
predictive values ( NPV) with exact binominal confidence intervals (30), based on the population 
prevalence of each outcome. Statistical analysis was performed using SAS software 9.2 (SAS Institute 
Inc., Cary, NC, USA) and a p-value of <0.05 was considered statistically significant. 
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Results 
In total 2,801 women were included in the analysis. Table 1 presents the maternal characteristics by 
pregnancy outcome. The mean maternal age was 32.8 (SD 4.7) years, 1266 (45.2%) women were 
nulliparous and 168 (6.1%) smoked during pregnancy. There were 218 (7.8%) SGA infants, 142 
(5.1%) preterm births, 73 (2.6%) women diagnosed with preeclampsia, 42 (1.5%) women had a 
miscarriage and 12 (0.4%) stillbirths. The median TSH levels for the total population was 0.84 UI/L 
(5–95th centile range: 0.08 – 2.37 UI/L) and for TSH (MoM) was 1.02 (5–95th centile range: 0.11 – 
2.92). Compared with unaffected pregnancies, median TSH levels were significantly higher in women 
with SGA <10th centile infants (P<0.01) and in women who had a preterm birth (<37 weeks) 
(P<0.05). 
 
The results of logistic regression analysis of TSH MoM for all pregnancy outcomes are shown in 
Table 2. High TSH MoM levels (>95th centile) were associated with increased risk of SGA (aOR 
1.71; 95% CI 0.99 – 2.94), preterm birth <37 weeks (aOR 1.86; 95% CI 1.00 – 3.45) and miscarriage 
(aOR 3.66; 95% CI 1.59 – 8.44); and there was a significant increased risk of preterm birth <37 weeks 
for women with levels above the 97.5th percentile (aOR 2.59; 95% CI 1.21 – 5.53). Overall high TSH 
MoM levels >95th and  >97.5th centile were associated with a 1.6 and 2.1 fold  risk of any adverse 
pregnancy outcome, respectively (Table 2). There was no significant association between high TSH 
levels and SGA <3rd centile, very preterm birth (<34 weeks), preeclampsia and stillbirth.  
                           
Figure 1 presents the ROC curves for the adjusted models based on TSH MoM levels >97.5th centile 
and Table 3 presents the predictive accuracy results for SGA <10th centile, preterm birth (<37 weeks), 
miscarriage and any adverse pregnancy outcome. Assessment of the accuracy of high TSH levels 
(>97.5th centile) revealed it performed poorly in predicting adverse pregnancy outcomes. The area 
under the curve (AUC) of most univariate models were not different from chance; and after adjusting 
for risk factors, the predictive accuracy remained inadequate in identifying subsequent pregnancy 
complications.  
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Discussion 
Our study highlights that women with high TSH levels at 10 to 14 weeks of pregnancy are at 
increased risk of experiencing an adverse pregnancy outcome, specially, having a small for gestational 
age infant (SGA <10th centile), preterm birth (<37 weeks) or miscarriage. Although we found no 
significant association for more severe outcomes of SGA <3rd centile, very preterm birth (<34 weeks), 
preeclampsia or stillbirth. Moreover, our results indicate that the predictive accuracy of high TSH 
levels was poor. Inclusion of additional maternal information and serum biomarker, β-hCG, did not 
improve results. 
 
Overall, our findings do not support routine screening for high TSH levels to identify adverse 
pregnancy outcomes. Application of our results to a general maternity population of 10,000 women 
with an estimated 10% prevalence of SGA reveal that screening for high levels of TSH in first 
trimester would identify 2,130 women at risk but only 420 would truly have a SGA infant. 1,710 
would be falsely labelled and a further 580 would be missed altogether.  This is supported by a recent 
trial comparing universal screening for TSH with a high risk case-finding approach for the detection 
and treatment of thyroid hormone dysfunction in pregnancy. The trial found no significant difference 
in adverse pregnancy outcomes between groups, although women from the universal screening group 
that were low-risk, hypothyroid and treated  had less adverse pregnancy outcomes compared with 
women from the case-finding group that were low-risk, hypothyroid (non-identified) and non-treated 
(18). These findings, as well as our own results, suggest that the majority of women having adverse 
pregnancy outcomes do not have elevated TSH and are euthyroid. Thus, TSH screening is likely to 
fail to identify the majority of women at risk because high TSH levels may represent only one specific 
pathological pathway, and the causes of adverse pregnancy outcomes are heterogeneous and 
multifactorial (31).  
To date, there have been a number of studies investigating the association between high TSH levels 
and adverse pregnancy outcomes and findings have been inconsistent. Although, our results suggest 
some evidence of an increased risk of SGA <10th centile and preterm birth (<37 weeks), these may 
have been chance findings as we did not find any relationship for more severe cases, SGA <3rd centile 
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and very preterm birth <34 weeks; however these numbers were small. The strong association 
between high TSH levels and miscarriage has not been reported by previous studies, but should be 
replicated in future studies. Although, a study of euthyroid pregnant women with autoimmune thyroid 
disease found a reduction in miscarriage rates in a group of women treated with Levothyroxine 
compared with a non-treated group that had higher TSH levels, suggesting that high TSH levels may 
be a determinant risk factor (32). Also, two studies have found increased risk of fetal loss, which 
included miscarriages and/or stillbirths (10, 11). Overall, our findings suggest there is significant 
association between high TSH levels and some adverse pregnancy outcomes examined. Variation in 
study findings may be explained by differences in study design, population sample size or 
representativeness of the clinical population, ranging from case-control studies of 167 women to large 
cohort studies testing over 17,000 women; and differences in demographic characteristics such as 
maternal age, racial origin or parity.  
 
Serum TSH was also variable across studies. We identified a 95th percentile cut point of 2.37 IU/L, 
although there is a degree of mild iodine deficiency in NSW (33)  results are consistent with an 
iodine-replete population and reference intervals reported for first trimester of pregnancy in Western 
Australia (34).  However, other studies have used various (95th and 97.5th centile) cut points to define 
high TSH levels, ranging from 2.78 to 4.8 IU/L (12, 14, 34-36). These differences suggest significant 
variability in distribution of TSH serum levels that may be explained by different levels of iodine 
status in populations, different immunoassay used in the analysis and underlying ethnic differences 
(37).   
  
Strengths of this study were the assessment of a large sample and unselected consecutive cohort of 
women attending first trimester screening. Record linkage of laboratory to birth and hospital data 
ensured follow up and ascertainment of pregnancy outcomes with only minimal missing information. 
Missing health and pregnancy information was mostly attributable to women residing in bordering 
towns and giving birth in hospitals out of state. Nevertheless, women with missing health information 
had similar characteristics compared to those included in the study.  Another strength was that the 
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exposure was measured independently of the outcome and were adjusted for β-hCG, with testing 
performed blinded to outcome.  Low β-hCG has been identified as a risk factor or marker for 
miscarriage, preterm delivery and fetal growth restriction (26, 38); and maternal TSH function in 
pregnancy can be influenced by the thyrotrophic activity of β-hCG. Both hormones have similar 
structure, sharing a common α-subunit, and a reduction in TSH secretion in response to rising β-hCG 
levels in the first trimester of pregnancy has been previously reported (1, 39). However, one of the 
limitations of our study was the lack of clinical information such as supplementation use in 
pregnancy. Nevertheless, women in our study appeared to be healthier,  reflected by the lower 
prevalence of adverse pregnancy outcomes  compared with the maternity population in NSW (5.1% 
vs. 5.9% preterm birth, 7.8% versus 10% SGA infants, 2.6% versus 3.1% preeclampsia) (40). Finally, 
miscarriages were underrepresented because these were limited to only those occurring post-10 weeks 
gestation and not all those women are admitted to hospital for such an event.  
 
In our study women were not tested for free thyroxine (fT4), therefore, it was only possible to 
categorize woman as having high TSH levels but not to separate women with subclinical (high TSH 
and fT4 within normal range) and clinical hypothyroidism (high TSH with fT4 <5th centile). Women 
with TSH levels of >10 mlIU/L, irrespective of their fT4 levels, are considered to have clinical 
hypothyroidism (19) In our population only four woman had TSH levels of >10 mlIU/L, 
consequently, the group was considered not significant to conduct a sub analysis.  Thyroid antibody 
presence (TPO-Ab or TG-Ab) was also not tested in our study. A recent meta-analysis of studies (41), 
found that miscarriage and preterm birth was associated with the presence of thyroid antibodies and 
that antibody positive women have, on average, higher TSH levels compared to antibody negative 
women. However, the predictive usefulness of high TSH levels for miscarriage is questionable due to 
the very limited time to intervention.   
 
Overall, our findings suggest that elevated TSH levels are associated with an increased risk of adverse 
pregnancy outcomes. Despite the positive associations, the poor predictive accuracy of our models 
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suggests that wide-spread screening for high levels of TSH in first trimester of pregnancy would not 
efficiently identify women at-risk of adverse pregnancy outcomes.  
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 Table 1: Maternal characteristics by pregnancy outcome  
 
                            P<0.05, **P<0.01, compared with unaffected women; MoM: Multiple of the median; SGA: Small for gestational age  
 
Maternal 
Characteristics 
(N=2801) 
Unaffected 
pregnancies 
N=2357 
n (%) 
SGA <10th  
N=218                       
n (%) 
SGA <3rd  
N=57                  
n (%) 
Preterm          
birth <37 
weeks  
N= 142                       
n (%) 
Preterm  
birth <34 
weeks  
N= 36                      
n (%) 
Preeclampsia 
N= 73 
n (%) 
Miscarriage 
N= 42             
n (%) 
Stillbirth   
N= 12                           
n (%) 
Age <35 years 1577 (66.9)  139 (63.8)  33 (57.9)  92 (64.8)  25 (69.4)  55 (75.3) 24 (57.1)  8 (66.7) 
Age ≥35 years  780 (33.1)   79 (36.2)  24 (42.1)  50 (35.2)  11 (30.56)  18 (24.7) 18 (42.9)  4 (33.3) 
Mean weight 
(SD) 67.4 (14.4)  61.0 (11.8)
** 59.4 (11.2)**  67.1 (14.6) 66.4 (11.7) 72.9 (16.7) 67.5 (16.5) 65.4 (4.5) 
Nulliparous 1018 (43.2) 129 (59.2) 34 (59.7) 66 (46.5) 13 (36.1) 48 (65.8) 23 (54.8)  6 (50.0) 
Smoking  133 (5.7) 25 (11.5) 9 (15.8) 11 (7.9)  2 (5.6)  1 (1.4) - 1 (11.1) 
TSH (UI/L) 
Median             
(5th - 95th) 
0.82  
(0.08 - 2.22) 
0.96  
(0.09 - 2.83)** 
0.84  
(0.10 - 2.78) 
0.92  
(0.14 - 3.22)* 
0.87  
(0.14 - 2.96) 
0.90  
(0.21 - 2.24) 
0.95  
(0.05 - 3.33) 
0.93  
(0.23 - 2.01) 
TSH MoM  
Median           
(5th - 95th) 
1.00  
(0.09 - 2.78) 
1.15  
(0.11 - 3.61)** 
1.02  
(0.12 - 3.36) 
1.11  
(0.16 - 4.00)* 
1.05  
(0.16 - 3.66) 
1.15  
(0.30 - 2.89) 
1.13  
(0.06 - 4.12) 
1.12  
(0.28 - 2.35) 
TSH MoM   
>95th centile 106 (4.8) 17 (8.1) 4 (7.1) 12 (8.8) 3 (8.3) 3 (4.2) 7 (18) 0 
TSH MoM  
5th - 95th centile 2127 (95.3) 192 (91.9) 52 (92.9) 125 (91.2) 33 (91.7) 68 (95.8) 32 (82.1) 12 (100) 
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 Table 2: Logistic Regression results of  
TSH MoM on adverse pregnancy outcomes  
Birth Outcome 
High 
TSH 
cases 
Adj OR             
(95% CI)* 
P 
value 
SGA <10th centile    
>95th (MoM=2.92) 17 1.71          (0.99 - 2.94) 0.05 
>97.5th (MoM=3.74) 9 1.76           (0.84 - 3.67) 0.13 
SGA <3rd centile    
>95th (MoM=2.92) 4 1.46          (0.51 - 4.14) 0.48 
>97.5th (MoM=3.74) 2 1.33          (0.31 - 5.70) 0.70 
Preterm Birth                 
(<37 weeks)    
>95th (MoM=2.92) 12 1.86          (1.00 - 3.45) 0.05 
>97.5th (MoM=3.74) 8 2.59          (1.21 - 5.53) 0.01 
Preterm Birth                 
(<34 weeks)    
>95th  (MoM=2.92) 3 1.77          (0.54 - 5.85) 0.35 
>97.5th(MoM=3.74) 1 NA NA 
Preeclampsia    
>95th (MoM=2.92) 3 0.84          (0.26 - 2.72) 0.77 
>97.5th (MoM=3.74) 1 NA NA 
Miscarriage    
>95th (MoM=2.92) 7 3.66          (1.59 - 8.44) 0.002 
>97.5th (MoM=3.74) 3 3.06          (0.92 - 10.22) 0.07 
Stillbirth    
>95th (MoM=2.92) 0 NA NA 
>97.5th (MoM=3.74) 0 NA NA 
Any adverse 
outcome    
>95th (MoM=2.92) 34 1.64          (1.10 - 2.47) 0.02 
>97.5th (MoM=3.74) 20 2.10          (1.23 - 3.59) 0.01 
             
           * Adjusted for maternal age, maternal weight, smoking,  
               parity or free β-hCG 
  SGA: Small for gestational age 
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Table 3: Screening results of TSH (MoM) >97.5th centile predicting adverse pregnancy  
          outcomes  
Birth 
outcome 
AUC  
(95% CI) P-value 
Sensitivity 
(%)   
(95%CI) 
Specificity 
(%)        
(95%CI) 
PPV 
(%)       
(95%CI) 
NPV 
(%)      
(95%CI) 
LR (+) 
SGA <10th 
centile 
Univariate 
 
0.51  
(0.50 - 0.52) 0.2 
4.1               
(1.9 - 7.7) 
97.7               
(97.0 - 98.2) 
13.4                    
(6.3 - 24.0) 
92.2                     
(91.1 - 93.2) 1.79 
Adjusted 0.69  (0.65 - 0.73) <0.001 
71.1           
(64.9 - 77.3) 
55.7               
(53.8 -57.7) 
12.2          
(10.5 - 14.2) 
95.7          
(94.6 - 96.7) 1.61 
Preterm     
Birth  
(<37 weeks) 
       
Univariate 
 
0.52  
(0.50 - 0.54) 0.08 
5.6               
(2.5 - 10.8) 
97.7               
(97.1 - 98.3) 
11.9            
(5.3 - 22.2) 
95.0          
(94.1 - 95.8) 2.49 
Adjusted 0.56  (0.51 - 0.61) 0.02 
69.7           
(61.5 - 77.1) 
34.4               
(32.6 - 36.3) 
5.5              
(4.5 - 6.6) 
95.4          
(93.9 - 96.7) 1.06 
Miscarriage        
Univariate 
 
0.52  
(0.48 - 0.56) 0.24 
7.1               
(1.5 - 19.5) 
97.6               
(96.9 - 98.1) 
4.3              
(0.9 - 12.0) 
98.6          
(98.1 - 99.0) 2.94 
Adjusted 0.70 (0.61 - 0.79) <0.001 
69.0           
(52.9 - 82.4) 
54.8               
(52.9 - 56.7) 
2.3              
(1.5 - 3.3) 
99.1          
(98.5 - 99.5) 1.53 
Any 
adverse 
outcome 
       
Univariate 
 
0.51          
(0.50 - 0.52) 0.02 
4.5              
(2.8 - 6.9) 
97.9            
(97.2 - 98.4) 
28.6          
(18.4 - 40.6) 
84.5       
(83.1 - 85.8) 2.14 
Adjusted 0.63          (0.60 - 0.65) <0.001 
75.8          
(71.6 - 79.8) 
41.4            
(39.4 - 43.4) 
19.6          
(17.7 - 21.5) 
90.1       
(88.2 - 91.8) 1.29 
           
          AUC: area under the Receiver Operating Characteristics (ROC) curves 
          AUC are test for significance against chance (0.5) 
            Models were adjusted for maternal age, weight, smoking, parity or free β-hCG 
            SGA: Small for gestational age; PPV: Positive predictive value; NPV: Negative predictive value;  
            LR (+): Positive likelihood ratio. 
 
 
 
 
 
 
